Clinical Trial Update: A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tralokinumab for moderate-to-severe atopic hand eczema has completed. The study, sponsored by LEO Pharma, aimed to evaluate efficacy an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Hand Eczema

Drugs mentioned

• Tralokinumab (tralokinumab)

Snippet

Sponsor: LEO Pharma | Conditions: Atopic Dermatitis, Atopic Hand Eczema | Phase 3 | Status: COMPLETED